The earnings call presented a mixed performance with solid revenue growth in several segments and strategic advancements in biosimilars and environmental achievements. However, challenges remain with declines in the U.S. generics market and a decrease in gross profit margins, along with regulatory observations from the USFDA.

Company Guidance

During Dr. Reddy's Laboratories' Q1 FY '26 earnings call, the company reported a steady double-digit revenue growth of 11% year-over-year, translating to INR 8,545 crores (USD 997 million). The EBITDA margin stood at 26.7%, slightly surpassing their target of 25%. However, the gross profit margin decreased by 350 basis points year-over-year to 56.9%, mainly due to price erosion in the generic segment, particularly lenalidomide. The SG&A expenses rose 13% year-over-year to INR 2,565 crores (USD 299 million), driven by strategic investments in consumer health care and nutraceuticals. R&D spend was INR 624 crores (USD 73 million), accounting for 7.3% of sales. The company maintained a net cash surplus of INR 2,922 crores (USD 341 million) and hedged USD 648 million using derivative contracts. The effective tax rate for the quarter was 25.9%, with the profit after tax reaching INR 1,419 crores (USD 166 million). Looking ahead, Dr. Reddy's anticipates growth driven by new product launches and strategic investments, although the U.S. generics market showed some softness.

Double-Digit Revenue Growth

Revenue grew by 11% year-over-year, driven by broad-based performance across most markets, except the U.S. generics business.

Biosimilar Business Momentum

Gained momentum through strategic collaboration with Alvotech for pembrolizumab, a biosimilar Keytruda, and sustained commitment to biosimilar development.

Environmental Leadership

Dr. Reddy's Carbon Disclosure Project (CDP) rating was elevated to an A, placing it among the top 2% globally.

India Business Growth

India business delivered a double-digit year-on-year growth of 11% with a 13% sequential increase, driven by new products and pricing.

Dr Reddy's Laboratories (RDY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RDY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2026 (Q2)	0.20 / -	0.178	―	―	―
Jul 29, 2025	2026 (Q1)	0.21 / 0.20	0.199	-1.01% (>-0.01)
May 09, 2025	2025 (Q4)	0.21 / 0.22	0.188	19.15% (+0.04)
Jan 23, 2025	2025 (Q3)	0.21 / 0.20	0.199	-1.01% (>-0.01)	―
Nov 05, 2024	2025 (Q2)	0.21 / 0.18	0.213	-16.43% (-0.04)	―
Jul 27, 2024	2025 (Q1)	0.19 / 0.20	0.206	-3.40% (>-0.01)	―
May 07, 2024	2024 (Q4)	0.18 / 0.19	0.14	34.29% (+0.05)	―
Jan 30, 2024	2024 (Q3)	0.18 / 0.20	0.184	8.15% (+0.02)	―
Oct 27, 2023	2024 (Q2)	0.17 / 0.21	0.162	31.48% (+0.05)	―
Jul 26, 2023	2024 (Q1)	0.15 / 0.21	0.179	15.08% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RDY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$14.70	$14.76	+0.41%
May 09, 2025	$13.11	$13.33	+1.68%
Jan 23, 2025	$15.01	$14.08	-6.20%
Nov 05, 2024	$14.72	$14.54	-1.22%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dr. Reddy's Laboratories Ltd (RDY) report earnings?

Dr. Reddy's Laboratories Ltd (RDY) is schdueled to report earning on Oct 24, 2025, Before Open (Confirmed).

What is Dr. Reddy's Laboratories Ltd (RDY) earnings time?

Dr. Reddy's Laboratories Ltd (RDY) earnings time is at Oct 24, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RDY EPS forecast?

RDY EPS forecast for the fiscal quarter 2026 (Q2) is 0.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing